PER percheron therapeutics limited

Ann: Topline Six-Month Results From Phase IIb Study of Avicursen, page-98

  1. 1,149 Posts.
    lightbulb Created with Sketch. 88
    Feel for the holders here. Bio's are easily the highest risk stock to punt on. Been burnt many times in the past and have realised that you make more money with the bounce from heavy selling after it fails as opposed to holding on for positive results unless you entered very low.

    Have hardly seen any small bio's become the next pharma giant, its a real punt on results. Long wait times and lots of capital raise. Its either you lose 80% of your money or you get 800%, hardly any inbetween.

    On that note, the company still has a decent amount of cash from the looks of things. Probably lots of tax loss selling happening right now.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
0.9¢
Change
-0.001(10.0%)
Mkt cap ! $9.786M
Open High Low Value Volume
1.0¢ 1.0¢ 0.9¢ $94.66K 10.09M

Buyers (Bids)

No. Vol. Price($)
4 661860 0.9¢
 

Sellers (Offers)

Price($) Vol. No.
1.0¢ 1588275 6
View Market Depth
Last trade - 15.52pm 27/06/2025 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.